Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.210
+0.040 (3.42%)
Sep 24, 2026, 2:43 PM EDT - Market open
Immuron Employees
Immuron had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$762,327
Profits / Employee
-$379,374
Market Cap
10.46M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 1 | 16.67% |
| Jun 30, 2023 | 6 | 1 | 20.00% |
| Jun 30, 2022 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Senti Biosciences Holdings | 39 |
| Enlivex | 34 |
| IN8bio | 18 |
| Moleculin Biotech | 17 |
| Theriva Biologics | 16 |
| Azitra | 13 |
| Purple Biotech | 10 |
IMRN News
- 20 days ago - Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up - Nasdaq
- 20 days ago - Immuron to launch Proibs in the U.S. - TheFly
- 20 days ago - Immuron to launch PROIBS® in the United States - GlobeNewsWire
- 27 days ago - Immuron FY26 Revenue Rises 6% As Net Loss Narrows And Cash Surges - Nasdaq
- 2 months ago - Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year - GlobeNewsWire
- 2 months ago - Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy - GlobeNewsWire
- 5 months ago - Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 - Accesswire
- 5 months ago - Immuron Double Digit 3Q Sales Growth - GlobeNewsWire